Close Menu

NEW YORK (GenomeWeb)  Consumer genomics company 23andMe let customers know this week that it will restrict its application programming interface (API) to select third-party apps.

The firm said that in two weeks it would disable other apps' ability to access customers' 23andMe results through its API. In effect, customers that have shared their 23andMe reports with other apps through its API may no longer work.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.